<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108690</url>
  </required_header>
  <id_info>
    <org_study_id>2015-768</org_study_id>
    <nct_id>NCT03108690</nct_id>
  </id_info>
  <brief_title>Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia</brief_title>
  <official_title>Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sara Thønnings</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates whether Therapeutic Drug Monitoring (TDM) and continuous infusion (CI)
      of beta-lactam antibiotics optimises target concentrations in patients with bacteraemia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target concentrations.</measure>
    <time_frame>30 days after intervention.</time_frame>
    <description>Serum concentrations within the target values for intervention. Following beta-lactams is included in the study: Benzylpenicillin, ampicillin, dicloxacillin, piperacillin/tazobactam, cefuroxime and meropenem.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity.</measure>
    <time_frame>30 days after intervention.</time_frame>
    <description>Diagnoses compared between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days until medically discharged.</measure>
    <time_frame>30 days after intervention.</time_frame>
    <description>Number of days until medically discharged compared between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failed antibiotic treatments.</measure>
    <time_frame>30 days after intervention.</time_frame>
    <description>Adding an additional antibiotic and/or change to a different antibiotic (not including a more narrow spectrum antibiotic) compared between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of antibiotic used.</measure>
    <time_frame>30 days after intervention.</time_frame>
    <description>Defined daly doses of antibiotic therapy compared between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic side effects and complications.</measure>
    <time_frame>30 days after intervention.</time_frame>
    <description>The severity of bacteraemia, mechanical ventilation and start-up of dialysis compared between the two arms. Growth of antibiotic-associated pathogenic in patient material compared between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality.</measure>
    <time_frame>30 days after intervention.</time_frame>
    <description>30-day mortality compared between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal clinical data and/or abnormal laboratory values.</measure>
    <time_frame>30 days after intervention.</time_frame>
    <description>Clinical data includes height, weight, heart rate, blood pressure, respiratory rate, Glasgow Coma Scale score, body temperature, fous of infection, the severity of bacteraemia, dialysis and laboratory values includes hemoglobin, white blood cells, neutrophils, thrombocytes, C-reactive protein, sodium, potassium, creatinine, albumin, lactate dehydrogenase, alanine amino transferase and lactate. Both will be compared between the two arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>TDM and CI.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous infusion of beta-lactam antibiotics. Therapeutic drug monitoring of beta-lactam antibiotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Beta-lactam antibiotics given as intermittent infusion. Samples of serum concentration of beta-lactam will be collected for comparison, but blinded during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continuous infusion of beta-lactam antibiotics .</intervention_name>
    <description>Beta-lactam antibiotic will be administered as continous infusion.</description>
    <arm_group_label>TDM and CI.</arm_group_label>
    <other_name>Benzylpenicillin</other_name>
    <other_name>Ampicillin</other_name>
    <other_name>Dicloxacillin</other_name>
    <other_name>Piperacillin/tazobactam</other_name>
    <other_name>Cefuroxime</other_name>
    <other_name>Meropenem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Therapeutic drug monitoring of beta-lactam antibiotics.</intervention_name>
    <description>Dosage of beta-lactam antibiotics will be adjusted according to serum concentration.</description>
    <arm_group_label>TDM and CI.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a positive blood culture.

          -  Undergo treatment with either intravenous penicillin, ampicillin,
             piperacillin/tazobactam, dicloxacillin, cefuroxime or meropenem.

          -  Hospitalised at Hvidovre University Hospital.

          -  Age ≥ 18.

          -  Able to understand and give informed consent.

          -  Included in the study within 24 hours after the final positive blood culture answer.

        Exclusion Criteria:

          -  Positive blood culture is interpreted as contamination.

          -  The patient dies before the intervention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Thønnings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Thønnings, MD</last_name>
    <phone>+45 38621783</phone>
    <email>sara.thoennings@regionh.dk</email>
  </overall_contact>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Sara Thønnings</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Therapeutic drug monitoring</keyword>
  <keyword>Continuous infusion</keyword>
  <keyword>Beta-lactam</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>Bacteraemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Lactams</mesh_term>
    <mesh_term>beta-Lactams</mesh_term>
    <mesh_term>Dicloxacillin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

